ProKidney Corp. PROK
1.14 USD +0.03 (+2.71%)
Nov 11, 2026, 11:57 AM EST
1.13 Day range 1.17
0.87 52-week range 2.88
- YTD
- -49.10%
- 1 year
- -59.28%
News
benzinga.com ProKidney Corp. Enters $200 Million At-The-Market Offering Agreement With Jefferies On October 29, 2026, ProKidney Corp. (the "Company") entered into an Open Market Sale AgreementSM (the "Sales Agreement") with Jefferies LLC (the "Sales Agent"), pursuant to which the Company may
benzinga.com Citigroup Maintains Buy on ProKidney, Lowers Price Target to $8 Citigroup analyst Yigal Nochomovitz maintains ProKidney (NASDAQ:PROK) with a Buy and lowers the price target from $10 to $8.
benzinga.com ProKidney Q2 EPS $(0.15) Misses $(0.14) Estimate, Sales $150.000K Beat $149.000K Estimate ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.14) by 7.14 percent. This is a 15.38 percent decrease over losses of $(0.13)…
benzinga.com AEVEX, Abivax, Watts Water Technologies And Other Big Stocks Moving Higher On Tuesday Stocks up, Dow Jones +100 points. AEVEX Corp shares rose 11.8% on $50m Air Force contract. Other big gainers: ABVX +34.2%, ESBA +20.9%, AVAV +20.4%, AIRJ +17.4%, FCEL +14%, UMAC +11.1%, HSAI +10.7%,…
benzinga.com Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrollment of first patient in phase 3 trial.- benzinga.com HC Wainwright & Co. Reiterates Buy on ProKidney, Maintains $12 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates ProKidney (NASDAQ:PROK) with a Buy and maintains $12 price target.
- benzinga.com ProKidney Q1 EPS $(0.14), Inline, Sales $226.000K Beat $143.667K Estimate ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This is a 7.69 percent decrease over losses of $(0.13) per share from the same period…
benzinga.com ProKidney Q4 EPS $(0.14) Misses $(0.11) Estimate, Sales $225.000K Beat $83.333K Estimate ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.11) by 23.89 percent. This is a 12.5 percent increase over losses of $(0.16)…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com This MYR Group Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - benzinga.com HC Wainwright & Co. Initiates Coverage On ProKidney with Buy Rating, Announces Price Target of $12 HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on ProKidney (NASDAQ:PROK) with a Buy rating and announces Price Target of $12.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today's Session 
benzinga.com ProKidney Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $217.000K Beat $44.250K Estimate ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 13.04 percent. This is a 14.29 percent increase over losses of $(0.14)…
benzinga.com ProKidney To Present LAte-Breaking Poster On Phase 2 REGEN-007 Trial Results At American Society of Nephrology's Kidney Week WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic…
benzinga.com ProKidney Corp. Signs New $19.1M Agreement To Sell Greensboro, NC Property After Prior Deal Termination As previously disclosed, on May 8, 2025, ProKidney Corp. (the "Company"), through its wholly owned subsidiary, ProKidney Acquisition Company, LLC ("Acquisition Sub"), entered into a purchase and sale…
benzinga.com SPAC King Chamath Palihapitiya Tells Retail Investors To Stay Away From His New SPAC Chamath Palihapitiya is back with another SPAC. This time he's telling retail investors to stay away. Here's why.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Chamath Palihapitiya Returns To SPACs: Past 18 Deals, Investments Average Loss Of 14% Chamath Palihapitiya is back with a new SPAC. Many investors will remember past SPACs the investor was involved with and the poor performance track record.
benzinga.com ProKidney Q2 EPS $(0.13) Beats $(0.15) Estimate, Sales $221.000K ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 18.75 percent increase over losses of $(0.16)…- benzinga.com Watching ProKidney Corp; Zacks Upgrades Stock To Strong Buy https://www.zacks.com/stock/news/2589077/prokidney-cp-prok-upgraded-to-strong-buy-what-does-it-mean-for-the-stock
- benzinga.com UBS Maintains Buy on ProKidney, Raises Price Target to $8 UBS analyst Eliana Merle maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $4 to $8.
benzinga.com Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - benzinga.com ProKidney Confirms Alignment With FDA On Accelerated Approval Pathway For Rilparencel FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT 1…
- benzinga.com Guggenheim Maintains Buy on ProKidney, Raises Price Target to $7 Guggenheim analyst Vamil Divan maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $6 to $7.
- benzinga.com Guggenheim Maintains Buy on ProKidney, Raises Price Target to $7 Guggenheim analyst Vamil Divan maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $6 to $7.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com AZZ Posts Better-Than-Expected Earnings, Joins MP Materials, WK Kellogg And Other Big Stocks Moving Higher On Thursday 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket - benzinga.com Citigroup Maintains Buy on ProKidney, Raises Price Target to $9 Citigroup analyst Yigal Nochomovitz maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $6 to $9.
benzinga.com ProKidney (PROK) Shares Skyrocket On Promising Kidney Disease Drug Trial Results ProKidney shares are trading sharply higher Wednesday morning. The stock is gaining following a marked surge on Tuesday driven by positive clinical trial data for its CKD treatment.
benzinga.com Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com US Stocks Likely To Open Higher: Trump's Tariff Clock Ticks, Fed Likely To Keep Rates Unchanged U.S. stock futures advanced on Wednesday after ending on a mixed note on Tuesday. Futures of major benchmark indices were trading higher.
benzinga.com Why AES Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket Shares of The AES Corporation (NYSE:AES) rose sharply in pre-market trading following reports the company has received takeover interest.
benzinga.com Dow Tumbles Over 150 Points Amid Trump Tariffs: Investor Sentiment Declines, Fear Index Moves To 'Greed' Zone - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com US Stocks Mixed; Small Business Sentiment Falls In June - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Top 3 Health Care Stocks You'll Regret Missing This Quarter - benzinga.com Why Contango Ore Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- benzinga.com Why Calavo Growers Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
- benzinga.com Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic…
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During the session on Thursday, 461 stocks hit new 52-week lows.
- benzinga.com Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the…
- benzinga.com Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session Gainers Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001.
- benzinga.com Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday's Mid-Day Session Gainers Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal…
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 258 companies hit new 52-week lows.